Cook Medical introduces Evolution for lead extraction
The company said that Evolution requires less surgical finesse and is more intuitive to use than laser-powered systems. It is also designed to negotiate chronic heavily fibrosed and
South Korea-based Alteogen has signed an exclusive licensing deal worth up to $365m with a global pharmaceutical company, granting worldwide rights to develop and commercialise a subcutaneous biologic product using its Hybrozyme technology.